Myriad Genetics Inc. (MYGN)
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
Myriad Genetics, Inc. MYGN is well-placed for growth in the coming quarters due to its steady rollout of new testing panels and product enhancements. The company is also progressing in its Cancer Care Continuum strategy, supported by rising demand in hereditary cancer and a 2026 launch calendar.
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.03 per share a year ago.
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics: SOTP Suggests The Company Is Undervalued
Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. The strongest part of the business is still the core Hereditary Cancer franchise, which has shown better resilience than other units through stronger volume trends and steadier operating performance. Even on a conservative sum-of-the-parts basis, the stock appears undervalued, with an estimated value of about $6.05 per share versus the current market price. Followed by portfolio simplification can bring further upside.
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
